Citius Oncology, Inc. Share-based Payment Arrangement, Expense
Citius Oncology, Inc. (CTOR) reported Share-based Payment Arrangement, Expense of $8.12 million for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2025-12-23
- Citius Oncology, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $2.09M, a 25.58% increase year-over-year.
- Citius Oncology, Inc. share-based payment arrangement, expense for the quarter ending 2025-06-30 was $2.13M, a 8.60% increase year-over-year.
- Citius Oncology, Inc. share-based payment arrangement, expense for the quarter ending 2025-03-31 was $2.09M, a 6.72% increase year-over-year.
- Citius Oncology, Inc. share-based payment arrangement, expense for the quarter ending 2024-12-31 was $1.81M, a 5.66% decline year-over-year.
- Citius Oncology, Inc. share-based payment arrangement, expense for fiscal 2025 was $8.12M, a 8.24% increase from fiscal 2024.
- Citius Oncology, Inc. share-based payment arrangement, expense for fiscal 2024 was $7.50M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $4.22M derived: sum of 2 quarters · filed 2025-12-23 | $6.31M derived: sum of 3 quarters · filed 2025-12-23 | $8.12M 10-K · filed 2025-12-23 |
| 2025-06-30 | $2.13M 10-Q · filed 2025-08-12 | $4.21M derived: sum of 2 quarters · filed 2025-08-12 | $6.02M 10-Q · filed 2025-08-12 | $7.69M derived: sum of 4 quarters · filed 2025-12-23 |
| 2025-03-31 | $2.09M 10-Q · filed 2025-05-14 | $3.90M 10-Q · filed 2025-05-14 | $5.56M derived: sum of 3 quarters · filed 2025-12-23 | $7.52M derived: sum of 4 quarters · filed 2025-12-23 |
| 2024-12-31 | $1.81M 10-Q · filed 2025-02-14 | $3.48M derived: sum of 2 quarters · filed 2025-12-23 | $5.43M derived: sum of 3 quarters · filed 2025-12-23 | $7.39M derived: sum of 4 quarters · filed 2025-12-23 |
| 2024-09-30 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $3.62M derived: sum of 2 quarters · filed 2025-12-23 | $5.58M derived: sum of 3 quarters · filed 2025-12-23 | $7.50M 10-K · filed 2025-12-23 |
| 2024-06-30 | $1.96M 10-Q · filed 2025-08-12 | $3.91M derived: sum of 2 quarters · filed 2025-08-12 | $5.83M 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $1.96M 10-Q · filed 2025-05-14 | $3.87M 10-Q · filed 2025-05-14 | ||
| 2023-12-31 | $1.92M 10-Q · filed 2025-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |